Bemiparin sodium

Bemiparin sodium
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	91449-79-5^N
ATC code	B01AB12 (WHO)
ChemSpider	none
Chemical data
Molar mass	3600 g/mol (average)
^NY (what is this?) (verify)

Bemiparin is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).^[1]

Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 g/mol on average.^[2] (Enoxaparin has 4500 g/mol) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.^[3]

References

↑ Chapman TM, Goa KL (2003). "Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis". Drugs 63 (21): 2357–77. doi:10.2165/00003495-200363210-00009. PMID 14524738.
↑ Planès, A. (2003). "Review of bemiparin sodium – a new second-generation low molecular weight heparinand its applications in venous thromboembolism". Expert Opinion on Pharmacotherapy 4 (9): 1551–1561. doi:10.1517/14656566.4.9.1551. PMID 12943485.
↑ Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H. L. N.; Viskov, C. (2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin". Thrombosis Research 128 (4): 361–367. doi:10.1016/j.thromres.2011.03.001. PMID 21458847.

bemiparin at the US National Library of Medicine Medical Subject Headings (MeSH)

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Tirofiban Roxifiban Orbofiban

ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor

Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil

COX inhibitors	Acetylsalicylic acid/Aspirin^# Aloxiprin Carbasalate calcium Indobufen Triflusal

Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+Aspirin) Picotamide Receptor antagonists Terutroban^†

Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal

Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low molecular weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin^‡ Oligosaccharides Fondaparinux Idraparinux^§ Heparinoids Danaparoid Dermatan sulfate Sulodexide

Direct Xa inhibitors	Xabans Apixaban Betrixaban^† Darexaban^§ Edoxaban Otamixaban^§ Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.